The board of directors confirmed the payout will reach stockholders of record by the close of business on July 15, 2026. Checks are scheduled for distribution on August 14, 2026. This latest declaration reinforces the company’s standing within the S&P Dividend Aristocrats Index, a benchmark reserved for corporations that maintain at least 25 consecutive years of annual dividend increases. Since spinning off from Abbott Laboratories in 2013, AbbVie has prioritized consistent shareholder distributions alongside its core investments in immunology, oncology, and neuroscience research.